Fluminorex

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 04:15, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fluminorex
Clinical data
ATC code
  • none
Identifiers
  • (RS)-5-[4-(trifluoromethyl)phenyl]-4,5-dihydro-1,3-oxazol-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H9F3N2O
Molar mass230.190 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • FC(F)(F)c1ccc(cc1)C2O\C(=N/C2)N
  • InChI=1S/C10H9F3N2O/c11-10(12,13)7-3-1-6(2-4-7)8-5-15-9(14)16-8/h1-4,8H,5H2,(H2,14,15) checkY
  • Key:NMGYDYBWRZHLHR-UHFFFAOYSA-N checkY
  (verify)

Fluminorex is a centrally acting sympathomimetic which is related to other drugs such as aminorex and pemoline. It was developed as an appetite suppressant by McNeil Laboratories in the 1950s.[1]

See also

References

  1. ^ US Patent 3278382 - 2-amino-5-aryloxazoline compositions and methods of using same